Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Frovocimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Frovocimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Frovocimab. |
| Estrone | Estrone may increase the thrombogenic activities of Frovocimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Frovocimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Frovocimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Frovocimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Frovocimab. |
| Estriol | Estriol may increase the thrombogenic activities of Frovocimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Frovocimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Frovocimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Frovocimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Frovocimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Frovocimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Frovocimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Frovocimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Frovocimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Frovocimab. |
| Equol | Equol may increase the thrombogenic activities of Frovocimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Frovocimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Frovocimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Frovocimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Frovocimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Frovocimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Frovocimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Frovocimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Frovocimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Frovocimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Frovocimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Frovocimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Frovocimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Frovocimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Frovocimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Frovocimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Frovocimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Frovocimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Frovocimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Frovocimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Frovocimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Frovocimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Frovocimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Frovocimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Frovocimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Frovocimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Frovocimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Frovocimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Frovocimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Frovocimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Frovocimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Frovocimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Frovocimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Frovocimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Frovocimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Frovocimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Frovocimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Frovocimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Frovocimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Frovocimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Frovocimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Frovocimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Frovocimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Frovocimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Frovocimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Frovocimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Frovocimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Frovocimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Frovocimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Frovocimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Frovocimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Frovocimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Frovocimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Frovocimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Frovocimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Frovocimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Frovocimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Frovocimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Frovocimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Frovocimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Frovocimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Frovocimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Frovocimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Frovocimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Frovocimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Frovocimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Frovocimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Frovocimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Frovocimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Frovocimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Frovocimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Frovocimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Frovocimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Frovocimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Frovocimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Frovocimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Frovocimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Frovocimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Frovocimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Frovocimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Frovocimab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Frovocimab. |